



Varicella Zoster Virus: Recent Advances, Risks and Prevention in Infants and Adults in Particular (during Immunomodulating Therapy)

Guest Editor:

Prof. Dr. Françoise Lunel-Fabiani

CHU Angers, France

Deadline for manuscript
submissions:

closed (30 November 2021)

Message from the Guest Editor

Varicella zoster virus (VZV) is a worldwide pathogen and may result in many complications. As it remains dormant in the nervous system, VZV, which is responsible for herpes zoster in sometimes severe forms, may reactivate later in life. A decrease in the effectiveness of the cellular immune responses due to age, disease, or treatments may explain the increased risk of herpes zoster in populations exhibiting these risk factors.

A live attenuated VZV vaccine is available and was approved by FDA in 1995. Vaccination is recommended in some countries like the US and Australia.

A live attenuated herpes zoster vaccine has been proven effective and safe in immunocompetent patients. The effectiveness and safety of the herpes zoster vaccine in patients with immunodeficiencies has also been recently demonstrated.

This Special Issue will focus on recent research related to the epidemiology of VZV in infants and adults, and recent advances in prevention (vaccination), treatment, and management of varicella and herpes zoster in immunocompromised patients.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.**

Journal Rank: JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com